Sensei Biotherapeutics
SNSEClinical Pipeline
No assets found matching the corporate key (SNSE)
Financial Statements & Analysis
Total Gross Revenue
— — — —
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
— — — —
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($2.67M) ($2.31M) ($11.33M) ($19.71M)
Operating Income / (Loss)
($5.21M) ($4.85M) ($22.29M) ($170.63M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
— — — —
Interest & Debt Servicing Expense
($0.01M) ($0.01M) ($0.03M) —
Other Non-Operating Income / (Expense)
($0.00M) $0.00M ($0.00M) ($0.00M)
Income Tax Provision / (Benefit)
$0.00M $0.00M $0.00M $0.00M
NET INCOME / (NET LOSS)
($4.94M) ($4.57M) ($21.09M) ($170.24M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$12.6M$10.6M$8.7M$152.3M
Short-Term Marketable Investments
// --// --// --// --
Total Liquid Cash Resources
$12.6M$10.6M$8.7M$152.3M
Accounts Receivable, Net
// --// --// --// --
Prepaid Expenses & Other Current Assets
$0.8M$0.5M$0.2M$1.0M
Total Current Assets
$29.6M$25.8M$21.5M$204.2M
Property, Plant and Equipment, Net
$0.1M$0.1M$0.1M$0.1M
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$31.8M$27.6M$22.9M$205.4M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
$0.4M$0.3M$0.7M$3.4M
Accrued Expenses & Clinical Liabilities
$0.7M$1.0M$0.7M$5.4M
Total Current Liabilities
$3.9M$4.4M$4.3M$14.2M
Long-Term Corporate Debt Balances
// --// --// --// --
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$0.6M$0.1M$0.1M$0.0M
Total Liabilities Block
$4.5M$4.6M$4.3M$14.2M
Total Stockholders' Equity
$27.3M$23.0M$18.6M$-137.3M
TOTAL LIABILITIES & EQUITY
$31.8M$27.6M$22.9M$-123.1M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
7.64x 5.81x 5.06x 14.39x
R&D Expenditure Flow
// --// --// --// --
Net Income / (Loss)
($4.94M) ($4.57M) ($21.09M) ($170.24M)
Depreciation & Amortization
$0.06M $0.09M $0.12M $0.03M
Stock-Based Compensation
$0.72M $0.98M $1.27M $12.90M
Change in Accounts Receivable
— — — —
Change in Prepaid Assets / Expenses
$0.35M $0.02M ($0.24M) ($10.74M)
Change in Payables & Clinical Accruals
($0.11M) $0.16M $0.23M ($0.10M)
Other Operating Source / (Use) Changes
($9.10M) ($13.27M) ($0.75M) $157.42M
Net Cash from Operating Activities
($13.00M) ($16.59M) ($20.45M) ($10.73M)
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
($0.02M) ($0.02M) ($0.02M) ($0.01M)
Purchases of Marketable Securities
— — — —
Maturities & Sales of Investments
— — — —
Net Cash from Investing Activities
$15.95M $17.69M $19.77M ($31.44M)
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
— — — —
Net Cash from Financing Activities
($0.38M) ($0.53M) ($0.65M) $185.83M
NET CONSOLIDATED CHANGE IN CASH
$2.56M $0.57M ($1.33M) $143.66M
Clinical Trials Registry
No active clinical trials detected in data stream.